Fiche publication
Date publication
janvier 2016
Journal
Drug design, development and therapy
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BINDA Delphine
,
Pr TOUSSIROT Eric
Tous les auteurs :
Toussirot E, Vauchy C, Binda D, Michel F
Lien Pubmed
Résumé
Axial spondyloarthritis (Ax SpA) refers to chronic inflammatory rheumatic diseases that mainly affect the axial skeleton, leading to erosions and new bone formation in the sacroiliac joints and/or the spine. Ax SpA includes the radiographic form of the disease, ie, ankylosing spondylitis (AS), and the nonradiographic Ax SpA (non-Rx Ax SpA) forms. Anti-tumor necrosis factor alpha (TNFα) agents are used in the treatment of Ax SpA in patients who do not respond to or are intolerant to nonsteroidal anti-inflammatory drugs. In these patients, anti-TNFα agents show promising results by targeting the inflammatory process and providing symptomatic relief. Golimumab is a fully human anti-TNFα agent that is currently approved for the treatment of both AS and non-Rx Ax SpA in Europe. This review focuses on the results of clinical trials with golimumab for the treatment of AS (GO-RAISE studies) and non-Rx Ax SpA (GO-AHEAD study) and on the effects of this agent on imaging findings (radiographic progression, magnetic resonance imaging inflammation) as well as on biological parameters. Overall, golimumab is a valid therapeutic option in patients with AS and non-Rx Ax SpA in Europe.
Mots clés
Anti-Inflammatory Agents, Non-Steroidal, pharmacology, Antibodies, Monoclonal, pharmacology, Antirheumatic Agents, pharmacology, Clinical Trials as Topic, Humans, Spondylitis, Ankylosing, drug therapy, Tumor Necrosis Factor-alpha, antagonists & inhibitors
Référence
Drug Des Devel Ther. 2016 ;10:2087-94
